MedImmune: collaboration with Trellis strengthens RSV pipeline

Friday, June 11, 2010 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

MedImmune: collaboration with Trellis strengthens RSV pipeline MedImmune has agreed to license the rights to develop Trellis Biosciences monoclonal antibody products for the treatment of respiratory syncytial virus (RSV). MedImmune already has one RSV
product on the market and has filed for motavizumab its follow-on compound. However the efficacy of both products can be improved upon which may have driven MedImmunes decision to collaborate with Trellis. (
) Trellis Bioscience has granted a worldwide exclusive license to MedImmune the global biologics unit of AstraZeneca to develop and commercialize Trellis antibodies directed against the respiratory syncytial virus (RSV). The RSV antibodies were discovered using Trellis proprietary CellSpot discovery platform which enables rapid identification and isolation of human antibodies produced from the B-cells of RSV-infected patients. The deal’s value could reach $338 million if a product reaches the market. MedImmune already has one marketed RSV antibody product (Synagis; palivizumab) which is currently the only available drug for prophylaxis of RSV infection. Synagis was approved in June 1998 for the prevention of serious respiratory disease caused by RSV in infants and children with a history of preterm birth (less than or equal to 35 weeks gestation) or chronic liver disease (CLD). While it has successfully reduced RSV hospitalizations in this high risk population its clinical efficacy can still be improved upon. Recognizing Synagis shortcomings MedImmune developed a follow-on compound motavizumab. This antibody has to-date demonstrated non-inferiority to Synagis but does not offer any significant improvements in terms of efficacy. The company filed for approval of motavizumab in January 2008 but received a Complete Response Letter (CRL) from the FDA asking for additional information. It is yet unclear whether MedImmune has addressed the regulators questions. In addition to motavizumab the company is also developing an extended half-life RSV monoclonal antibody two vaccines for RSV prophylaxis and an F-protein inhibitor for the treatment of RSV infection. MedImmunes collaboration with Trellis comes as a logical step considering the attractive market gap for RSV therapies with improved efficacy. Given that motavizumab does not offer any significant therapeutic benefits over Synagis and the extended release version will only offer improvements in terms of administration it is likely that MedImmune will develop Trellis RSV antibodies as successors to motavizumab and may also use them in combination with other RSV products. Other companies with RSV products in development include Pevion Biotech which has an RSV vaccine in preclinical stages and Cubist Pharmaceuticals which is developing Alnylams RNAi-based RSV inhibitors. Related research • Monoclonal antibodies: 2009 update Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Follow us on twitter:

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store